Cessatech A/S
Cessatech A/S is a Danish biopharmaceutical company focused on developing pediatric medicines for acute care settings. Its pipeline centers on non-invasive treatments designed to address unmet needs in children, including a fixed-dose nasal spray for acute pain and intranasal sedation programs.
Business
Share of revenueNon-invasive medicine designed to treat acute pain in children.
Intranasal sedation candidates intended for medical procedures in children.
Early-stage concept for a ready-to-use local anaesthetic gel.
Customers
Cessatech's customers are primarily healthcare systems and medical professionals involved in pediatric treatment, including hospitals, clinics, and procedural care settings. The products are aimed at situations where children need pain relief or sedation without invasive administration, which matters in emergency care and diagnostic procedures.
Buy CT001 and future pediatric treatments for acute pain management in children.
Use CT002 for non-invasive sedation during procedures such as MRI scans.
Need child-appropriate pain treatment options that are fast and non-invasive.
Evaluate pediatric medicines for adoption across hospital systems and care pathways.
Strategy
The company's strategy is to advance a small pipeline of pediatric assets from development into regulatory approval and commercialization. A key priority is bringing CT001 through review and launch while keeping follow-on programs such as CT002 and CT003 moving toward clinical or preclinical milestones.
It is the lead program and the most advanced asset in the pipeline.
It broadens the pipeline and addresses procedural sedation needs in children.
It extends the company's pediatric platform into a new local anaesthetic concept.
Geography
Cessatech is based in Denmark and develops products for use in both the US and Europe. The annual report indicates CT001 is in pre-launch preparation in these markets, making regulatory pathways and market access in those regions especially important.
Risks
Cessatech faces the typical risks of an early-stage biopharmaceutical company, especially regulatory, clinical, and commercialization execution risk. The report also highlights going-concern uncertainty and the absence of marketed products, which makes future funding, launch timing, and product acceptance critical to the business.
- Going-concern uncertaintyImpact: CriticalLikelihood: High
The auditor noted material uncertainty because the company currently has no product on market.
Exposure: Company-wide financing and continuity
- Regulatory approval riskImpact: HighLikelihood: Medium
CT001 and other programs depend on approval pathways before commercialization.
Exposure - Clinical development riskImpact: HighLikelihood: Medium
Pediatric drug candidates can fail or require further studies before launch.
Exposure: Pipeline assets
- Market adoption riskImpact: MediumLikelihood: Medium
Hospitals and clinicians must accept the products into care pathways and procurement systems.
Exposure: Commercial launch
Accounting
Judgemental itemsThe auditor explicitly noted material uncertainty about the company's ability to continue as a going concern.
Impact: Can affect classification of assets and liabilities and overall financial statement basis
Pipeline development creates judgment over whether costs are expensed or recognized as assets.
Impact: Directly affects operating results and balance-sheet asset values
The value of CT001, CT002, and CT003 depends on assumptions about approval and market success.
Impact: Potential impairment risk if assumptions weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
Nasus Pharma Ltd
NSRX · Pharmaceutical Preparations
Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products.
Sedana Medical
SEDANA · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
Grace Therapeutics, Inc.
GRCE · Pharmaceutical Preparations
SenesTech, Inc.
SNES · Agricultural Chemicals
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Contineum Therapeutics, Inc.
CTNM · Pharmaceutical Preparations
Last updated: 24/10/2026